Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 15;7(1):e05967.
doi: 10.1016/j.heliyon.2021.e05967. eCollection 2021 Jan.

Time-in-range as a target in type 2 diabetes: An urgent need

Banshi Saboo  1 , Jothydev Kesavadev  2 , Arun Shankar  2 , Meera B Krishna  2 , Shruti Sheth  1 , Vidisha Patel  1 , Gopika Krishnan  2
Affiliations
Review

Time-in-range as a target in type 2 diabetes: An urgent need

Banshi Saboo et al. Heliyon. .

Abstract

Time-in-range emerged as a valuable blood glucose metric, 'beyond HbA1c' for a deeper insight into glycemic control in people with diabetes. It denotes the proportion of time that a person's glucose level remains within the desired target range (usually 70-180 mg/dL or 3.9-10.0 mmol/L). Though clinical targets in the current recommendations for type 1 and type 2 diabetes are close enough, their clinical profiles and prevalences are quite different. Type 2 diabetes is the commonest form of diabetes. Many clinical trials have challenged the usefulness of HbA1c as a glycemic target for Type 2 diabetes mellitus. On account of the higher prevalence and complications of type 2 diabetes, more outcomes-based studies are needed to associate time-in-range with its ongoing risk. These studies strongly support the dependability of time-in-range to identify patients with elevated risk in type 2 diabetes. We discuss the utility of time-in-range, a new metric of continuous glucose monitoring as an outcome measure to correlate with type 2 diabetes risks and complications and to analyze the effectiveness of type 2 diabetes management. This approach may support the use of time-in-range as a metric for long-term health outcomes in the type 2 diabetes population.

Keywords: Continuous glucose monitoring; HbA1c; Time-in-range; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Battelino T., Danne T., Bergenstal R.M. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593–1603. - PMC - PubMed
    1. Advani A. Positioning time in range in diabetes management. Diabetologia. 2020;63:242–252. - PubMed
    1. Totomirova T., Arnaudova M., Daskalova I. 900-P: HbA1c is an insufficient glucose control assessment tool in type 1 and type 2 treated with insulin. Diabetes. 2020;69:900.
    1. Tylee T.S., Trence D.L. Glycemic variability: looking beyond the A1C. Diabetes Spectr. 2012;25:149–153.
    1. Group UKPDS (UKPDS) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. - PubMed

LinkOut - more resources